ELINOGREL POTASSIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H14ClFN5O5S2.K
Molecular Weight	562.035
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].CNC1=C(F)C=C2C(=O)N(C(=O)NC2=C1)C3=CC=C(NC(=O)[N-]S(=O)(=O)C4=CC=C(Cl)S4)C=C3

InChI

InChIKey=PPADHTVWIWCEDE-UHFFFAOYSA-M

InChI=1S/C20H15ClFN5O5S2.K/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17;/h2-9H,1H3,(H4,23,24,25,26,28,29,30);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20608816
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800022611 | http://www.wikidoc.org/index.php/Elinogrel

Elinogrel, previously known as PRT060128 or PRT128, is a direct-acting, reversible P2Y12 inhibitor for both intravenous and oral administration. Elinogrel has been tested in 2 phase II studies for the treatment of acute coronary syndrome, myocardial infarction and prevention of secondary thrombotic events. Elinogrel therapy was associated with an increased incidence of dyspnea and incidence of elevated liver transaminases. The development of the drug was terminated in January 2012 by Novartis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Purinergic receptor P2Y12 23 Target ID: CHEMBL2001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20608816	Antagonist 2778		23.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Myocardial infarction 121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19958867	Primary		Phase II 1132	Unknown Approved Use Unknown
Percutaneous coronary intervention 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22647518	Preventing		Phase II 1132	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
150 mg 2 times / day multiple, oral (max) Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22647518 Page: p.339, 340	unhealthy, ADULT n = 408 Health Status: unhealthy Condition: coronary artery disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 408 Sources: https://pubmed.ncbi.nlm.nih.gov/22647518 Page: p.339, 340	Disc. AE: Dyspnea... AEs leading to discontinuation/dose reduction: Dyspnea (grade 1-2, 1%) Sources: https://pubmed.ncbi.nlm.nih.gov/22647518 Page: p.339, 340

AEs

AE	Significance	Dose	Population
Dyspnea	grade 1-2, 1% Disc. AE	150 mg 2 times / day multiple, oral (max) Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22647518 Page: p.339, 340	unhealthy, ADULT n = 408 Health Status: unhealthy Condition: coronary artery disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 408 Sources: https://pubmed.ncbi.nlm.nih.gov/22647518 Page: p.339, 340

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00H1KW	https://www.1pchem.com/search?query=1P00H1KW
Chem Scene	CS-0002993	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0002993
Compound Cloud	16066663
Compound Cloud	23718927
Hairui	HR110297	http://www.hairuichem.com/en/product/search.do?q=HR110297
MedChem Express	HY-11021	https://www.medchemexpress.com/search.html?q=HY-11021&ft=&fa=&fp=
MolPort	MolPort-035-941-202	https://www.molport.com/shop/molecule-link/MolPort-035-941-202
MuseChem	I006640	https://www.musechem.com/product/I006640.html
Tocris	5316	https://www.tocris.com/search.php?Type=QuickSearch&Value=5316

PubMed

Title	Date	PubMed
Emerging antiplatelet agents, differential pharmacology, and clinical utility.	2010	22282687
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.	2010 Feb 1	20050853
Elinogrel: pharmacological principles, preclinical and early phase clinical testing.	2010 Jul	20608816
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).	2010 Jul	20598974
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.	2010 Nov 2	20800407
Newer antithrombotic drugs.	2010 Oct	21572750

Patents

Sample Use Guides

In Vivo Use Guide

80-mg intravenous bolus of elinogrel was given immediately before percutaneous coronary intervention, followed by twice-daily oral elinogrel administration of 50, 100, or 150 mg for 60 days

Route of Administration: Other

In Vitro Use Guide

When two concentrations of elinogrel (2.5 or 5.0 mmol/l) were added in vitro to the blood of diabetic patients, an anti-thrombotic effect was observed, supporting evidence that elinogrel may overcome the limitation of poor clopidogrel response.

Name

Type

Language

ELINOGREL POTASSIUM

Official Name

English

Elinogrel Potassium [WHO-DD]

Common Name

English

ELINOGREL POTASSIUM SALT [MI]

Common Name

English

PRT060128-POTASSIUM

Code

English

PRT-060128 POTASSIUM

Code

English

PRT060128 POTASSIUM

Common Name

English

ELINOGREL POTASSIUM [USAN]

Common Name

English

2-THIOPHENESULFONAMIDE, 5-CHLORO-N-(((4-(6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL)PHENYL)AMINO)CARBONYL)-, MONOPOTASSIUM SALT

Common Name

English

POTASSIUM ((5-CHLORO-2-THIENYL)SULFONYL)((4-(6-FLUORO-7-(METHYLAMINO)-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL)PHENYL)CARBAMOYL)AZANIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C80483